Last reviewed · How we verify

ketamine + clonidine

Irmandade da Santa Casa de Misericordia de Sao Paulo · Phase 3 active Small molecule

Ketamine acts as an NMDA receptor antagonist, while clonidine is an alpha-2 adrenergic receptor agonist.

Ketamine acts as an NMDA receptor antagonist, while clonidine is an alpha-2 adrenergic receptor agonist. Used for Treatment-resistant depression.

At a glance

Generic nameketamine + clonidine
SponsorIrmandade da Santa Casa de Misericordia de Sao Paulo
TargetNMDA receptor, alpha-2 adrenergic receptor
ModalitySmall molecule
Therapeutic areaPain management
PhasePhase 3

Mechanism of action

Ketamine's mechanism of action involves blocking the NMDA receptor, which is involved in the transmission of pain signals. Clonidine, on the other hand, works by stimulating alpha-2 adrenergic receptors, which can help reduce sympathetic nervous system activity and lower blood pressure.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: